-
公开(公告)号:EP4271210B1
公开(公告)日:2024-10-30
申请号:EP21848192.7
申请日:2021-12-28
IPC分类号: A23L33/105 , A61K36/87 , A61K31/122 , A61K31/19 , A61K31/352 , A61P27/06 , A61K36/45
-
公开(公告)号:EP4434515A1
公开(公告)日:2024-09-25
申请号:EP23382276.6
申请日:2023-03-24
IPC分类号: A61K9/00 , A61K9/107 , A61K31/00 , A61K33/00 , A61P27/04 , A61P27/06 , A61K47/02 , A61K47/10 , A61K47/36
CPC分类号: A61K9/0048 , A61K31/658 , A61K9/1075 , A61P27/06 , A61P27/04 , A61K47/10 , A61K47/36 , A61K47/02
摘要: The invention provides an aqueous micellar solution comprising micelles of poloxamer, with a hydrophilic surface and a hydrophobic nucleus encapsulating CBD, which solution can additionally comprise NaCl, H3BO3, and sodium hyaluronate, and which is for use in the prevention and/or treatment of glaucoma, and/or high intraocular pressure, ocular dryness, ocular discomfort or pain and/or high mechanical ocular sensitivity. The administration of the micellar solution in drops to the eyes gives rise to a decrease in the intraocular pressure after repeated administration, preferably for seven days or more, without increasing mechanical corneal sensitivity or spontaneous tear production. The decrease in intraocular pressure should prevent or slow glaucoma appearance or development. Compositions for the same use, comprising the aqueous micellar solution, are also provided.
-
公开(公告)号:EP4412994A1
公开(公告)日:2024-08-14
申请号:EP22798034.9
申请日:2022-10-06
发明人: ELLIS, David, Archer , GORDHAN, Heeren, M. , LICHOROWIC, Cynthia, L. , STURDIVANT, Jill, M. , DELONG, Mitchell, A.
IPC分类号: C07D401/04 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04 , A61P9/00 , A61P27/06 , A61P29/00 , A61P35/00 , A61K31/506
CPC分类号: C07D401/04 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04 , A61P35/00 , A61P29/00 , A61P27/06 , A61P9/00
-
公开(公告)号:EP3466408B1
公开(公告)日:2024-07-31
申请号:EP18202240.0
申请日:2011-11-10
IPC分类号: A61K9/00 , A61K9/08 , A61K31/7048 , A61K47/24 , A61K31/4168 , A61P27/06 , A61P3/10 , A61P29/00 , A61P9/10 , A61P31/04 , A61P31/12 , A61K31/405 , A61P27/02 , A61K31/57
CPC分类号: A61K9/0051 , A61K9/08 , A61K47/24 , A61K9/0048 , A61K31/405 , A61K31/4168 , A61K31/57 , A61K31/573 , A61K31/7048 , A61P27/02 , A61P27/06 , A61P29/00 , A61P31/04 , A61P31/12 , A61P9/10 , A61P3/10
-
公开(公告)号:EP4401750A1
公开(公告)日:2024-07-24
申请号:EP22789185.0
申请日:2022-09-14
发明人: DOYLE, Sarah , ADAMSON, Peter , CAMPBELL, Matthew
CPC分类号: A61K38/20 , A61P27/06 , A61K45/06 , C07K16/22 , C07K2317/2420130101 , A61K2039/50520130101
-
公开(公告)号:EP3099304B1
公开(公告)日:2024-07-17
申请号:EP15743644.5
申请日:2015-01-30
IPC分类号: A61K31/549 , A61K9/02 , A61P27/06 , A61K31/353 , A61K31/675 , C07F9/6547 , C07F9/6558 , C07D405/04 , C07D405/12 , C07D285/24
CPC分类号: A61K31/549 , A61K9/00 , A61K31/4025 , A61K31/4439 , A61K31/454 , A61K31/675 , C07D201/00 , C07D405/04 , C07D405/12 , C07D285/24 , A61K9/0048 , A61K9/0051 , A61K31/353 , C07D311/20 , C07D311/70 , C07D405/14 , A61P27/06
-
7.
公开(公告)号:EP4272743A3
公开(公告)日:2024-07-10
申请号:EP23177574.3
申请日:2012-09-19
申请人: Allergan, Inc.
发明人: Abad, Jaun Carlos
IPC分类号: A61K31/27 , A61K31/4164 , A61K31/4174 , A61K31/4178 , A61K31/5415 , A61K45/06 , A61P27/02 , A61P27/06 , A61P27/10 , A61K31/4025 , A61K31/415
CPC分类号: A61K45/06 , A61K9/0048 , A61K31/27 , A61K31/4164 , A61K31/4174 , A61K31/325 , A61K31/4178 , A61K31/5415 , A61K31/16 , A61K31/541 , A61P27/02 , A61P27/06 , A61P27/10
摘要: The present invention is directed to compositions and methods for treating ocular conditions, including presbyopia, mild hyperopia, irregular astigmatism, hyperopic accommodative esotropia, and glaucoma. The compositions can also be used to potentiate or enhance interventions that retard, reverse, or modify the aging process of the crystalline lens and its surrounding tissues. The compositions include a cholinergic agent, such as a muscarinic acetylcholine receptor M3 agonist, and an alpha agonist having an imidazoline group or a non-steroidal anti-inflammatory agent (NSAID) having COX-2 selectivity. It has been found that an alpha agonist having an imidazoline group or non-steroidal anti-inflammatory agent (NSAID) having COX-2 selectivity in combination with a cholinergic agent, such as pilocarpine, act synergistically to improve the accommodative and focusing ability of the eye while minimizing the side effects from each compound.
-
8.
公开(公告)号:EP4157844B1
公开(公告)日:2024-07-10
申请号:EP21728071.8
申请日:2021-05-25
IPC分类号: C07D487/04 , C07D491/14 , C07D471/14 , A61K31/519 , A61P35/00 , A61P15/10 , A61P17/06 , A61P25/00 , A61P25/02 , A61P25/04 , A61P27/02 , A61P27/06 , A61P29/00 , A61P31/12
CPC分类号: C07D487/04 , C07D491/14 , C07D471/14 , A61P35/00 , A61P31/12 , A61P27/02 , A61P27/06 , A61P25/00 , A61P25/02 , A61P25/04 , A61P17/06 , A61P29/00 , A61P15/10
-
公开(公告)号:EP4392139A1
公开(公告)日:2024-07-03
申请号:EP22769900.6
申请日:2022-08-24
申请人: Centre National de la Recherche Scientifique (CNRS) , Université de Montpellier , Ecole Nationale Supérieure de Chimie de Montpellier , Mt Act
发明人: ROGOWSKI, Krzysztof , AMBLARD-CAUSSIL, Muriel , VAN DER LAAN, Siem , VEZENKOV, Lubomir , MARCELLIN, Guillaume , LANNAY, Yoann , HACHED, Khaled
IPC分类号: A61P21/00 , A61K31/336 , A61P25/16 , A61P27/06 , A61P35/00 , C07D303/48 , C12Q1/37 , C07D403/04 , C07D405/10 , C07D417/12
CPC分类号: C07D303/48 , C12Q1/37 , A61P25/16 , A61P27/06 , A61P35/00 , A61P21/00 , C07D405/10 , C07D403/04 , C07D417/12
-
公开(公告)号:EP4356906A8
公开(公告)日:2024-07-03
申请号:EP23204633.4
申请日:2023-10-19
申请人: SIFI S.p.A.
IPC分类号: A61K31/185 , A61K9/48 , A61K31/352 , A61K31/353 , A61K31/525 , A61K31/7068 , A61P27/06
CPC分类号: A61K31/525 , A61K31/353 , A61K31/7068 , A61K31/352 , A61K31/185 , A61P27/06 , A61K9/4875
摘要: The present invention concerns a nutraceutical composition with a neuroprotective effect for the treatment of glaucoma, comprising riboflavin, epigallocatechin gallate, citicoline, forskolin, and homotaurine.
-
-
-
-
-
-
-
-
-